Shots:
- Viridian reported positive long-term durability data from the P-III (THRIVE) study evaluating 5 infusions of veligrotug (veli) or PBO (Q3W), with primary topline analysis at 15wks and follow-up to 52wks, in active thyroid eye disease (TED) pts. (N=30)
- Study demonstrated that 70% (21/30) were proptosis responders at 15wks. and maintained at least a 2 mm reduction in proptosis at week 52, with no significant worsening in the fellow eye; no new safety concerns were observed in the follow-up period
- Veligrotug met all 1EPs and 2EPs and demonstrated reduction and resolution of diplopia in both P-III (THRIVE) & (THRIVE-2) study. Viridianexpects the BLA submission in H2’25, with a potential market launch in 2026
Ref: Businesswire| Image: Viridian | Press Release
Related News:- Ionis Reveals Topline P-III (ESSENCE) Trial Data of Olezarsen for Moderate Hypertriglyceridemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
